Skip to main content
. 2024 Jun 22;150(6):315. doi: 10.1007/s00432-024-05823-1

Fig. 1.

Fig. 1

Correlation between DNAJC1 expression and clinicopathological characteristics of GBM. A DNAJC1 expression in different cancers from the TCGA database. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, low grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma. The expression of DNAJC1 in GBM samples and normal tissues from B TCGA, C GSE29796 or D CGGA. The expression of DNAJC1 in different E glioma grades, F IDH mutant status, G chromosome 1p/19q codeletion or H histological types. I Representative immunohistochemical staining of DNAJC1 in different histological gliomas using a tissue chip. * P < 0.05; ** P < 0.01; *** P < 0.001